Spyre Therapeutics, Inc. SYRE
At closeNov 10, 2026, 4:00 PM EST
After hours · Nov 10, 4:00 PM ET
- YTD
- +218.93%
- 1 year
- +371.06%
- Market cap
- 9.92B
- EPS (ttm)
- -2.49
- Shares out
- 94.97M
- Forward P/E
- -28.29
- YTD return
- +218.93%
- 1-year return
- +371.06%
- Volume
- 1.00M
- Avg volume
- 1.25M
- Open
- 106.95
- Previous close
- 109.00
- Day's range
- 103.19 – 109.15
- 52-week range
- 22.18 – 109.00
- Beta
- 3.23
- Analysts
- Strong Buy
- Price target
- 122.27 (+17.0%)
- Earnings date
- Feb 18, 2027
5D +5.95 (+6.04%)
Key statistics
- Enterprise value
- 9.43B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 10.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -95.36M
- Total cash
- 1.07B
- Total debt
- 0
- Return on equity
- -35.03%
- Short % of float
- 14.06%
- 50-day average
- 90.16
- 200-day average
- 75.24
Analyst view
Consensus: strong buy
- Target (low)
- 110.00
- Target (mean)
- 122.27
- Target (high)
- 135.00
- Strong buy1
- Buy16
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate -0.99766.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | -1.02 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.82227 | -0.94 | -0.12 | -14.32% |
| Aug 4, 2026 | Jun 30, 2026 | -0.75885 | -0.36 | +0.40 | +52.56% |
| May 5, 2026 | Mar 31, 2026 | -0.66 | -0.74 | -0.08 | -12.12% |
| Feb 19, 2026 | Dec 31, 2025 | -0.66 | -0.70 | -0.04 | -6.06% |
| Nov 4, 2025 | Sep 30, 2025 | -0.76076 | -0.15 | +0.61 | +80.28% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Guggenheim | main | Buy | Buy |
| Nov 4, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 1, 2026 | JP Morgan | init | — | Overweight |
| Oct 1, 2026 | BTIG | reit | Buy | Buy |
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- spyre.com
News
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? 
Spyre Therapeutics Announces Grants of Inducement Awards 
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $135 
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120 
Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session 
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target 
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120 
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
Your note
Sign in to keep a note on SYRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALBERS JEFFREY W | Director | Sale | Aug 6, 2026 | 0 |
| BURROWS SCOTT L. | Chief Financial Officer | Sale | Sep 1, 2026 | 79,762 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | Sale | Jun 22, 2026 | 0 |
| HENDERSON MICHAEL THOMAS | Director | Sale | Jun 21, 2026 | 68,606 |
| KING-JONES HEIDY | Officer | Sale | Sep 1, 2026 | 2,845 |
| SLOAN SHELDON | Officer | Sale | Jun 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.72% | 13,026,187 | 1.36B | Jun 29, 2026 |
| Blackrock Inc. | 6.85% | 6,506,605 | 679.81M | Jun 29, 2026 |
| Perceptive Advisors Llc | 4.55% | 4,319,496 | 451.30M | Jun 29, 2026 |
| RTW Investments LP | 4.48% | 4,251,996 | 444.25M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 4.04% | 3,840,778 | 401.28M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.63% | 3,448,681 | 360.32M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.91% | 2,760,132 | 288.38M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.61% | 2,482,298 | 259.35M | Jun 29, 2026 |
| SmallCap World Fund Inc | 2.37% | 2,247,758 | 234.85M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.09% | 1,982,310 | 207.11M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.79% | 1,699,846 | 177.60M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.94% | 896,559 | 93.67M | Jun 29, 2026 |